Bruker (NASDAQ:BRKR) Sees Unusually-High Trading Volume – Here’s Why

Shares of Bruker Corporation (NASDAQ:BRKR) saw an uptick in trading volume on Wednesday . 3,870,890 shares changed hands during mid-day trading, an increase of 67% from the previous session’s volume of 2,324,268 shares.The stock last traded at $44.7430 and had previously closed at $44.73.

Wall Street Analyst Weigh In

Several research firms recently commented on BRKR. TD Cowen lifted their price objective on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th. The Goldman Sachs Group reduced their price objective on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a report on Friday, February 13th. UBS Group lifted their price objective on Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Stifel Nicolaus set a $45.00 price objective on Bruker in a report on Friday, May 8th. Finally, Guggenheim reduced their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $50.54.

Bruker Trading Down 0.7%

The stock has a 50 day simple moving average of $37.48 and a 200-day simple moving average of $42.18. The firm has a market capitalization of $6.76 billion, a P/E ratio of -185.00, a P/E/G ratio of 2.59 and a beta of 1.12. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. The business had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.47 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker’s payout ratio is currently -83.33%.

Insider Activity

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bruker

A number of large investors have recently made changes to their positions in BRKR. Orbis Allan Gray Ltd bought a new stake in shares of Bruker during the 2nd quarter valued at about $192,735,000. Price T Rowe Associates Inc. MD lifted its position in shares of Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after buying an additional 2,289,269 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after buying an additional 1,850,215 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Bruker by 317.7% during the 4th quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Bruker by 222.6% during the 4th quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock valued at $86,663,000 after buying an additional 1,269,316 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.